SequelSEC

Stemtech Corp STEK

Wholesale-Drugs, Proprietaries & Druggists' Sundries · CIK 0001511820 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$629.31K
Fiscal year ended 2026-06-30
Operating income
-$125.57K
Fiscal year ended 2026-06-30
Free cash flow
-$54.84K
Fiscal year ended 2026-06-30

Stemtech Corp (STEK) reported revenue of $629.31K and net income of -$292.36K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Stemtech Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Wholesale-Drugs, Proprietaries & Druggists' Sundries.

Income

Stemtech Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$629.31K$462.96K$458.11K$852.30K$697.92K$868.05K$1.31M$1.03M$1.33M$1.38M
Cost of revenue$163.64K$109.30K$103.43K$169.82K$145.91K$147.78K$268.59K$380.20K$332.18K$345.37K
Gross profit$465.67K$353.65K$354.68K$682.48K$552.02K$720.26K$1.05M$651.42K$993.62K$1.04M
Operating income-$125.57K-$1.09M-$863.94K-$339.22K-$300.99K-$1.20M$33.16K-$716.47K-$692.31K-$1.01M
Net income-$292.36K-$1.25M-$1.48M-$809.41K-$293.14K-$1.46M-$396.58K-$1.17M-$784.16K-$1.42M
Research & development$0$0$0$0$0$0$0$0$0$0
Weighted-average diluted sharesshares 2.08Bshares 812.14MUnavailableshares 150.10Mshares 142.44Mshares 118.70MUnavailableshares 120.57Mshares 116.75Mshares 83.47M
Pretax income-$292.36K-$1.25M-$1.48M-$812.54K-$296.28K-$1.46M-$396.58K-$1.17M-$784.09K-$1.42M
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$0.00$0.00Unavailable$-0.01$0.00$-0.01Unavailable$-0.01$-0.01$-0.02
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$539.72K$1.40M$1.25M$882.44K$697.99K$1.73M$1.09M$1.18M$1.34M$1.62M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$103.26K

Balance

Stemtech Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$3.16M$3.25M$3.15M$3.76M$3.87M$3.75M$3.78MUnavailable$3.69M$3.61M
Current assets$571.23K$602.59K$457.06K$1.02M$1.10M$936.08K$921.75KUnavailable$617.87K$511.12K
Total liabilities$11.11M$11.06M$10.59M$10.30M$10.32M$9.44M$8.74MUnavailable$8.62M$8.06M
Current liabilities$11.11M$11.06M$10.59M$10.30M$10.32M$9.44M$8.74MUnavailable$8.62M$8.06M
Total equity incl. NCI-$8.22M-$8.08M-$7.70M-$6.55M-$6.45M-$5.68M-$5.23MUnavailable-$4.93M-$4.45M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$311.28K$325.70K$217.34K$234.61K$274.81K$188.40K$197.36KUnavailable$57.37K$57.51K
Accounts receivable$0$9.20K$0$326.49K$347.44K$260.31K$269.75KUnavailable$230.58K$116.70K
Goodwill$467.41K$467.41K$467.41K$467.41K$467.41K$467.41K$467.41KUnavailable$467.41K$467.41K
Long-term debt$4.40M$4.16M$4.16M$4.12M$4.14M$4.16M$3.82MUnavailable$3.73M$3.73M
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Stemtech Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$54.84K-$425.88K$127.00K$24.97K$74.95K-$710.51K-$270.92K-$1.17M-$176.36K$1.02M
Capital expenditures$0$0$0$0$0$0$0$0$0$0
Investing cash flow$0$0$0$0$0$0$0$0$0$0
Financing cash flow$200.16K-$22.84K$69.42K-$161.55K$473.38K$78.75K$1.01M$0$17.02K$51.72K
Net change in cash-$9.38K$17.90K-$17.17K-$17.03K-$33.39K$50.54K$1.17M-$1.17M-$14.43K$159.83K
Stock-based compensation$109.46K$108.26K$110.67K$110.67K$109.46K$108.26K$209.06K$0$121.73K$109.46K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$41.87K$41.87K$41.86K$41.88K$41.88K$41.88K$185.00K$0$5.33K$154.14K

Derived

Stemtech Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$54.84K-$425.88K$127.00K$24.97K$74.95K-$710.51K-$270.92K-$1.17M-$176.36K$1.02M
Gross margin74.0%76.4%77.4%80.1%79.1%83.0%79.6%63.1%74.9%75.0%
Operating margin-20.0%-236.4%-188.6%-39.8%-43.1%-138.8%2.5%-69.5%-52.2%-73.1%
FCF margin-8.7%-92.0%27.7%2.9%10.7%-81.9%-20.6%-113.5%-13.3%73.6%
SBC / revenue17.4%23.4%Unavailable13.0%15.7%12.5%Unavailable0.0%9.2%7.9%
Current ratio0.05x0.05x0.04x0.10x0.11x0.10x0.11xUnavailable0.07x0.06x
Revenue YoY growth-9.8%-46.7%-65.1%-17.4%-47.4%-37.2%-3.5%-20.5%17.5%22.0%
Net margin-46.5%-270.6%Unavailable-95.0%-42.0%-167.7%Unavailable-113.5%-59.1%-102.6%
R&D / revenue0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
CapEx / revenue0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open STEK in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-06-22View SEC filing
10-K · Filed 2026-05-29View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-07-17View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-06-30

Difference 2381052 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.